152 related articles for article (PubMed ID: 12369972)
1. Towards improved acetylcholinesterase inhibitors: a structural and computational approach.
Barril X; Orozco M; Luque FJ
Mini Rev Med Chem; 2001 Sep; 1(3):255-66. PubMed ID: 12369972
[TBL] [Abstract][Full Text] [Related]
2. Tacrine-huperzine A hybrids (huprines): a new class of highly potent and selective acetylcholinesterase inhibitors of interest for the treatment of Alzheimer's disease.
Camps P; Muñoz-Torrero D
Mini Rev Med Chem; 2001 Jul; 1(2):163-74. PubMed ID: 12369981
[TBL] [Abstract][Full Text] [Related]
3. Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs.
Kryger G; Silman I; Sussman JL
Structure; 1999 Mar; 7(3):297-307. PubMed ID: 10368299
[TBL] [Abstract][Full Text] [Related]
4. Peripheral and dual binding site acetylcholinesterase inhibitors: implications in treatment of Alzheimer's disease.
Castro A; Martinez A
Mini Rev Med Chem; 2001 Sep; 1(3):267-72. PubMed ID: 12369973
[TBL] [Abstract][Full Text] [Related]
5. Three-dimensional structure of a complex of galanthamine (Nivalin) with acetylcholinesterase from Torpedo californica: implications for the design of new anti-Alzheimer drugs.
Bartolucci C; Perola E; Pilger C; Fels G; Lamba D
Proteins; 2001 Feb; 42(2):182-91. PubMed ID: 11119642
[TBL] [Abstract][Full Text] [Related]
6. Structure-based 3D QSAR and design of novel acetylcholinesterase inhibitors.
Sippl W; Contreras JM; Parrot I; Rival YM; Wermuth CG
J Comput Aided Mol Des; 2001 May; 15(5):395-410. PubMed ID: 11394735
[TBL] [Abstract][Full Text] [Related]
7. New potent acetylcholinesterase inhibitors in the tetracyclic triterpene series.
Sauvaître T; Barlier M; Herlem D; Gresh N; Chiaroni A; Guenard D; Guillou C
J Med Chem; 2007 Nov; 50(22):5311-23. PubMed ID: 17902635
[TBL] [Abstract][Full Text] [Related]
8. Rational design of reversible acetylcholinesterase inhibitors.
Barril X; Kalko SG; Orozco M; Luque FJ
Mini Rev Med Chem; 2002 Feb; 2(1):27-36. PubMed ID: 12369955
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and evaluation of indanone derivatives as acetylcholinesterase inhibitors and metal-chelating agents.
Meng FC; Mao F; Shan WJ; Qin F; Huang L; Li XS
Bioorg Med Chem Lett; 2012 Jul; 22(13):4462-6. PubMed ID: 22633691
[TBL] [Abstract][Full Text] [Related]
10. Structural determinants of the multifunctional profile of dual binding site acetylcholinesterase inhibitors as anti-Alzheimer agents.
Galdeano C; Viayna E; Arroyo P; Bidon-Chanal A; Blas JR; Muñoz-Torrero D; Luque FJ
Curr Pharm Des; 2010; 16(25):2818-36. PubMed ID: 20698824
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and evaluation of flavonoid derivatives as potential multifunctional acetylcholinesterase inhibitors against Alzheimer's disease.
Li RS; Wang XB; Hu XJ; Kong LY
Bioorg Med Chem Lett; 2013 May; 23(9):2636-41. PubMed ID: 23511019
[TBL] [Abstract][Full Text] [Related]
12. [Design of acetylcholinesterase inhibitor for Alzheimer's disease therapy: from multi-binding site inhibitors to multi-target directed ligands].
Yang WC; Sun Q; Yu NX; Zhu XL; Yang GF
Yao Xue Xue Bao; 2012 Mar; 47(3):313-21. PubMed ID: 22645754
[TBL] [Abstract][Full Text] [Related]
13. Molecular modelling approaches to the design of acetylcholinesterase inhibitors: new challenges for the treatment of Alzheimer's disease.
Muñoz-Muriedas J; Lopez JM; Orozco M; Luque FJ
Curr Pharm Des; 2004; 10(25):3131-40. PubMed ID: 15544503
[TBL] [Abstract][Full Text] [Related]
14. Accurate prediction of the bound conformation of galanthamine in the active site of Torpedo californica acetylcholinesterase using molecular docking.
Pilger C; Bartolucci C; Lamba D; Tropsha A; Fels G
J Mol Graph Model; 2001; 19(3-4):288-96, 374-8. PubMed ID: 11449566
[TBL] [Abstract][Full Text] [Related]
15. Quinolone-benzylpiperidine derivatives as novel acetylcholinesterase inhibitor and antioxidant hybrids for Alzheimer disease.
Pudlo M; Luzet V; Ismaïli L; Tomassoli I; Iutzeler A; Refouvelet B
Bioorg Med Chem; 2014 Apr; 22(8):2496-507. PubMed ID: 24657052
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological evaluation of 3,6-diaryl-7H-thiazolo[3,2-b] [1,2,4]triazin-7-one derivatives as acetylcholinesterase inhibitors.
Jin Z; Yang L; Liu SJ; Wang J; Li S; Lin HQ; Wan DC; Hu C
Arch Pharm Res; 2010 Oct; 33(10):1641-9. PubMed ID: 21052939
[TBL] [Abstract][Full Text] [Related]
17. Structural determinants of Torpedo californica acetylcholinesterase inhibition by the novel and orally active carbamate based anti-alzheimer drug ganstigmine (CHF-2819).
Bartolucci C; Siotto M; Ghidini E; Amari G; Bolzoni PT; Racchi M; Villetti G; Delcanale M; Lamba D
J Med Chem; 2006 Aug; 49(17):5051-8. PubMed ID: 16913695
[TBL] [Abstract][Full Text] [Related]
18. 3D structure of Torpedo californica acetylcholinesterase complexed with huprine X at 2.1 A resolution: kinetic and molecular dynamic correlates.
Dvir H; Wong DM; Harel M; Barril X; Orozco M; Luque FJ; Muñoz-Torrero D; Camps P; Rosenberry TL; Silman I; Sussman JL
Biochemistry; 2002 Mar; 41(9):2970-81. PubMed ID: 11863435
[TBL] [Abstract][Full Text] [Related]
19. A structure-based design approach to the development of novel, reversible AChE inhibitors.
Doucet-Personeni C; Bentley PD; Fletcher RJ; Kinkaid A; Kryger G; Pirard B; Taylor A; Taylor R; Taylor J; Viner R; Silman I; Sussman JL; Greenblatt HM; Lewis T
J Med Chem; 2001 Sep; 44(20):3203-15. PubMed ID: 11563919
[TBL] [Abstract][Full Text] [Related]
20. Acetylcholinesterase inhibitors for potential use in Alzheimer's disease: molecular modeling, synthesis and kinetic evaluation of 11H-indeno-[1,2-b]-quinolin-10-ylamine derivatives.
Rampa A; Bisi A; Belluti F; Gobbi S; Valenti P; Andrisano V; Cavrini V; Cavalli A; Recanatini M
Bioorg Med Chem; 2000 Mar; 8(3):497-506. PubMed ID: 10732965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
